Kilitch Drugs shows strong earnings but underlying issues persist

Kilitch Drugs (India)'s healthy earnings may be misleading due to one-time gains and declining core margins. Revenue grew by 12% YoY, but operating profit growth was only 4%, indicating cost pressures. Debt levels remain elevated at ₹320 crore, raising concerns over sustainability.

📊 STOCKS: KILITCH | 🏢 SECTOR: Pharma | #MEDIUMIMPACT #Earnings